首頁 > 市場調查報告書 > 醫療設備

市場調查報告書

商品編碼

1345388

全球腦植入市場 - 2023-2030

Global Brain Implants Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

概述

全球腦植入市場在2022 年達到53 億美元，預計到2030 年將實現利潤豐厚的成長，達到108 億美元。全球腦植入市場預計在預測期內（2023-2023 年）年複合成長率為9.5% 2030）。

大腦植入物在各個領域都具有重要意義，因為它們具有直接與大腦交互並實現神經活動與外部設備之間通訊的潛力。無線技術的進步使大腦植入物能夠與外部設備進行通訊，而無需物理連接器。這一趨勢旨在提高使用大腦植入物的舒適度和舒適度，同時降低感染或與有線連接相關的其他併發症的風險。

此外，神經退行性疾病和精神疾病的數量不斷增加，並且對負擔得起的、有效的和永久性療法的需求未得到滿足。由於神經外科醫生和神經病學診所不斷努力提高人們對腦植入物的認知，腦植入物的市場規模正在不斷成長。

動力學

神經系統疾病的患病率不斷上升

神經系統疾病的增加有助於市場的擴張。例如，人們可以通過在腦組織中植入電極來刺激或記錄來自大腦各個部分的訊號。帕金森氏症經常使用腦植入物進行治療，特別是深部腦刺激（DBS）。帕金森氏症是一種神經退行性疾病，其特徵是產生多巴胺的腦細胞逐漸喪失。

馬達消耗會導致顫抖、僵硬、運動遲緩（運動緩慢）和姿勢不穩定等運動症狀。帕金森氏症的症狀是由異常的大腦活動引起的，而電刺激有助於控制這種異常的大腦活動。因此，帕金森氏症的增加有助於市場的擴張。

例如，據帕金森基金會稱，帕金森氏症（PD）影響著美國約一百萬人。到 2030 年，預計這一數位將達到 120 萬。繼阿滋海默症之後，帕金森氏症是最常見的神經退行性疾病。在美國，每年有近 90,000 人被診斷出帕金森氏症。全球有超過 1000 萬人患有帕金森氏症。因此，神經系統疾病的增加有助於市場的擴張。

公司重點發展戰略

由於市場對新技術的需求不斷增加，與腦植入相關的產品批准、產品發布、合作和收購有所增加。例如，2022年10月，為了更有效地治療神經系統疾病，神經技術公司Axoft開發的腦機介面（BMI）被指定為FDA突破性設備。該公司籌集了 800 萬美元資金，用於支持 FDA 的臨床前研究並擴大其“軟如大腦”神經植入物的原型。

此外，2023 年 5 月 26 日，埃隆·馬斯克 (Elon Musk) 及其神經技術企業 Neuralink 的聯合創始人宣布，美國食品和藥物管理局已批准該公司開展首次人體臨床研究。 The Link 是 Neuralink 正在開發的一種大腦植入物，旨在讓嚴重癱瘓的人僅利用神經訊號來操作外部技術。這表明，患有肌萎縮側索硬化症等晚期退行性疾病的人有一天可能會重新獲得用意念打字和移動光標的能力。由於上述因素，市場將在預測期內擴大。

與治療相關的高成本

大腦植入物的開發和植入成本可能很高。手術治療、術後護理和未來的小工具更換都包含在價格中。例如，不同的製造商對大腦植入物收取不同的價格。在美國，手術費用（包括植入設備、住院費用和麻醉費）從 35,000 美元到 100,000 美元不等。

獲得該技術可能會受到價格的阻礙，特別是對於那些負擔不起的人來說。此外，植入大腦需要高度複雜的手術技術，需要經驗豐富的神經外科醫生和配備尖端設備的手術室。手術、麻醉和術後護理可能會產生巨大的經濟費用。因此，上述因素將抑制市場的成長。

Brain implants hold significant importance across various fields due to their potential to interface directly with the brain and enable communication between neural activity and external devices. Advances in wireless technology were enabling brain implants to communicate with external devices without the need for physical connectors. The trend aimed to improve the comfort and comfort of using brain implants while also reducing the risk of infection or other complications associated with wired connections.

In addition, there is an increasing number of neurodegenerative and mental illnesses, as well as an unmet demand for affordable, effective, and permanent therapies. The market size for brain implants is growing as a result of increasing effort being made by neurosurgeons and neurology clinics to increase awareness of brain implants.

Dynamics

The Rising Prevalence of Neurological Diseases

The increase in neurological disorders contributes to the market's expansion. For instance, one can stimulate or record signals from various parts of the brain by implanting electrodes in the brain tissue. Parkinson's disease is frequently treated using brain implants, specifically Deep Brain Stimulation (DBS). Parkinson's disease is a neurodegenerative condition marked by a progressive loss of brain cells that produce dopamine.

Motor symptoms like tremors, stiffness, bradykinesia (slow movement), and postural instability are brought on by this dopamine depletion. The Parkinson's symptoms are caused by aberrant brain activity, which the electrical stimulation helps control. Thus, the rise in Parkinson's disease contributes to the market's expansion.

For instance, according to Parkinson's Foundation, stated that, Parkinson's disease (PD) affects around one million persons in the US. By 2030, it is anticipated that this number would reach 1.2 million. After Alzheimer's disease, Parkinson's disease is the most common neurodegenerative condition. In the United States, PD is yearly diagnosed in close to 90,000 individuals. Over 10 million people worldwide suffer with PD. Thus, the increase in neurological illnesses contributes to the market's expansion.

Key Development Strategies Followed by the Companies

The increase in the product approvals, product launches, collaborations and acquisitions related to brain implants owing to its increasing demand to novel technologies to the market. For instance, in October 2022, in order to more effectively treat neurological illnesses, the brain-machine interface (BMI) developed by the neurotechnology company Axoft was designated an FDA Breakthrough Device. The business raised $8 million in funding to support pre-clinical FDA research and scale up prototypes of its "soft as the brain" neural implants.

Additionally, on May 26, 2023, Elon Musk and his co-founders at the neurotech business Neuralink announced that the Food and Drug Administration had given the company permission to carry out its first in-human clinical investigation. The Link, a brain implant being developed by Neuralink, intends to enable individuals with severe paralysis to operate external technology only utilizing neural signals. This suggests that people with terminal degenerative illnesses like ALS may someday regain the ability to type and move cursors with their minds. Due of the above factors the market will expand in forecast period.

High Cost Associated with the Treatment

Brain implants can be costly to develop and implant. Surgical treatments, post-operative care, and prospective gadget replacements are all included in the price. For instance, different manufacturers charge different prices for brain implants. The price of surgery (including the implanted device, hospital expenses, and anesthesia) can range from $35,000 to $100,000 in the United States.

Access to the technology may be hampered by the price, especially for those who cannot afford it. Additionally, placing brain implants requires highly sophisticated surgical techniques that call for experienced neurosurgeons and an operating theater outfitted with cutting-edge equipment. Surgery, anesthesia, and post-operative care can come at a significant financial expense. Thus above factors will restrain the market growth.

Segment Analysis

The global brain implants market is segmented based ontype, material, application, end user and region.

The Alzheimer's Disease Accounted for Approximately 31.07% of the Brain Implants Market Share

Dementia, a condition marked by memory loss and cognitive decline, is one of the main causes of dementia. ReTypes are needed for diagnosis, treatment, care, and support services for affected people, placing a significant load on healthcare systems. Age is the major risk factor for Alzheimer's disease. A larger portion of the population is at an elevated risk of contracting the disease as the world's population continues to age. An individual's risk increases as they age.

The intricate combination of genetic, environmental, and lifestyle factors affects the risk of Alzheimer's disease. These elements may combine as people get older, raising the risk that they may have the illness. Thus, the increase in the elderly population drives segment growth.

For instance, according to Eurostat, the EU population in January 2022, was estimated to be 446.7 million, out of which 21.1% were Older individuals aged 65 or over indicating an increase of 0.3 percentage points (pp) to the previous year and an increase of 3.1 pp compared with a decade earlier.

In addition, according to a new report by the United Nations (UN), the number of individuals aged 65 years or above globally is anticipated to increase two folds in the next 30 years. The geriatric population is expected to attain 1.6 billion in 2050, making up over 16% of the world population. By thus increasing the geriatric population will drive the segment growth.

Geographical Penetration

North America Accounted for Approximately 42.6% of the Market Share in 2022

The brain implant market is dominated by North America. Due to the regulations that make healthcare inexpensive for the vast majority of the population in the region, the nation's healthcare facilities are of the greatest quality and are accessible to the wide population. The prevalence and incidence of numerous neurological illnesses are rising, which will accelerate the growth of the region.

For instance, according to Alzheimer's Association, more than 6 million Americans of all ages have Alzheimer's. In 2023, there will be 6.7 million Americans 65 and older who have Alzheimer's. 73% of people are 75 years of age or older. The proportion of Americans who have Alzheimer's disease or another kind of dementia will increase along with the size of the population in the United States who are 65 years of age and older. Barring technological advances that prevent or treat Alzheimer's disease, the estimated number of persons aged 65 and older with the condition may increase to 12.7 million by 2050.

Thus, the demand for neurological treatments including brain implants is fueled by the need to identify and treat these diseases, which is anticipated to lead to a growth in the number of product manufacturing companies in the nation. The market in the North American region has grown as a result of the rise in neurological diseases.

Competitive Landscape

The major global players in the brain implants market Medtronic PLC, Boston Scientific Corporation, Renishaw PLC, Synchron Inc, Abbott Laboratories, LivaNova PLC, NeuroPace Inc, Sapiens Neuro, Neuralink, Nexstim and others.

COVID-19 Impact Analysis

The covid has affected negatively due to several factors. The danger of infection is present throughout any surgical operation, including brain implant surgeries. Since COVID-19 is extremely contagious, catching it while having a brain implant could result in serious illness or difficulties.Access to medical care has been hampered throughout numerous locations due to the pandemic.

Due of COVID-19's impact on the healthcare system, people with brain implants may have trouble getting timely treatment or device changes. In many hospitals, brain implant surgery, such as DBS, is an elective surgical procedure, hence the scheduled surgeries have been postponed. When the restrictions were eased, procedures were carried out and patients were advised to maintain their most recent optimal dosing schedule.

By Type

Deep Brain Stimulator
Spinal Cord Stimulator
Vagus Nerve Stimulator

By Material

Silicon
Tungsten
Platinum-iridium
Nanotubes
Others

By Application

Alzheimer's Disease
Parkinson's Disease
Epilepsy
Chronic Pain
Others

By End User

Hospitals
Neurology clinics
Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

U.K.

France

Spain

Italy

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

Australia

Rest of Asia-Pacific

Middle East and Africa

Key Developments

In May 2022, in order to allow six severely paralyzed people to operate digital gadgets hands-free and with only their thoughts, Elon Musk's competitor firm Neuralink, Synchron, has started conducting human trials on the subject. The US-based Synchron competes with Elon Musk's Neuralink, which also seeks to let paralyzed people to use computers and phones through its brain activities alone. Both companies create endovascular brain-computer interfaces (BCIs).
In March 2021, one of the largest investments in the European medical nanotechnology sector to date has been made in a collaboration between two Barcelona institutions and the Nanomedicine Lab at The University of Manchester to treat brain disorders such as epilepsy and Parkinson's Disease.
In December 2022, the Eterna spinal cord stimulation (SCS) system from Abbott, the smallest implantable, rechargeable spinal cord stimulator currently available on the market for the treatment of chronic pain, received FDA approval. The only SCS waveform technology with the greatest level of clinical proof (1A evidence), low-dose BurstDR stimulation, is used in Eterna SCS and has been shown to relieve pain 23% more than conventional waveform technology methods.

Why Purchase the Report?

To visualize the global brain implants market segmentation based on type, material, application, end user and region as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of brain implants market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global brain implants market report would provide approximately 53 tables, 54 figures and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Type
3.2. Snippet by Material
3.3. Snippet by Application
3.4. Snippet by End User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The rising prevalence of neurological diseases
  - 4.1.1.2. Key Development Strategies Followed by the Companies
- 4.1.2. Restraints
  - 4.1.2.1. High cost associated with the treatment
- 4.1.3. Opportunity
  - 4.1.3.1. New avenues for treating mental health conditions
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. ByType

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Deep Brain Stimulator*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Spinal Cord Stimulator
7.4. Vagus Nerve Stimulator

8. ByMaterial

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 8.1.2. Market Attractiveness Index, By Material
8.2. Silicon*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Tungsten
8.4. Platinum-iridium
8.5. Nanotubes
8.6. Others

9. ByApplication

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Alzheimer's Disease l*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Parkinson's Disease
9.4. Epilepsy
9.5. Chronic Pain
9.6. Others

10. ByEnd User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Neurology clinics
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.7.1. U.S.
  - 11.2.7.2. Canada
  - 11.2.7.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.7.1. Germany
  - 11.3.7.2. U.K.
  - 11.3.7.3. France
  - 11.3.7.4. Spain
  - 11.3.7.5. Italy
  - 11.3.7.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.7.1. Brazil
  - 11.4.7.2. Argentina
  - 11.4.7.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.7.1. China
  - 11.5.7.2. India
  - 11.5.7.3. Japan
  - 11.5.7.4. Australia
  - 11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Material
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Medtronic PLC*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Boston Scientific Corporation
13.3. Renishaw PLC
13.4. Synchron Inc
13.5. Abbott Laboratories
13.6. LivaNova PLC
13.7. NeuroPace Inc
13.8. Sapiens Neuro
13.9. Neuralink
13.10. Nexstim

LIST NOT EXHAUSTIVE